Skip to main content
Clinical Trials/DRKS00026242
DRKS00026242
Not yet recruiting
Phase 4

Evaluation of the effect of immersive virtual reality-based upper extremity rehabilitation in hemiparesis and hemiplegia compared to standard therapeutic care: A randomized controlled trial.

ReHub GmbH0 sites112 target enrollmentFebruary 18, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
G81.0
Sponsor
ReHub GmbH
Enrollment
112
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 18, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ReHub GmbH

Eligibility Criteria

Inclusion Criteria

  • One of the following diagnoses:
  • \- ICD10 G81\.0: Flaccid hemiparesis and hemiplegia.
  • \- ICD10 G81\.1: Spastic hemiparesis and hemiplegia
  • \- ICD10 G81\.9: Hemiparesis and hemiplegia, unspecified
  • \- First cerebrovascular brain injury (stroke) 3 to 12 months ago
  • \- Age range: 40\-70 years
  • \- Ability to sit without support for more than 10 seconds
  • \- Ability to follow simple verbal instructions
  • \- No previous experience with Rehago or any other VR therapy app
  • \- Sufficient knowledge of German to operate the app

Exclusion Criteria

  • \- Symptomatic neurologic pre\-condition, especially chronic progressive or recurrent like Multiple sclerosis or severe Muscle diseases
  • \- Heart failure
  • \- debilitating chronic dizziness
  • \- Impaired vision
  • \- Severe intellectual disability or dementia
  • \- Mental illness with delusional perceptual processing
  • \- Photosensitive Epilepsy
  • \- Bilateral pareses of upper extremity
  • \- Severe Aphasia that prevents the use of the therapeutic device

Outcomes

Primary Outcomes

Not specified

Similar Trials